A systematic review of PCSK9 inhibitors alirocumab and evolocumab
M McDonagh, K Peterson, B Holzhammer… - Journal of managed care …, 2016 - jmcp.org
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a
new class of cholesterol-lowering medications that provide significant reductions in lipids but …
new class of cholesterol-lowering medications that provide significant reductions in lipids but …
Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
I Gouni‐Berthold, OS Descamps… - British journal of …, 2016 - Wiley Online Library
Aims Two anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal
antibodies, alirocumab and evolocumab, have been approved for the treatment of …
antibodies, alirocumab and evolocumab, have been approved for the treatment of …
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein
cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic …
cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic …
Evolocumab: a review in hyperlipidemia
GM Keating - American Journal of Cardiovascular Drugs, 2016 - Springer
Evolocumab (Repatha®) is a monoclonal antibody targeting proprotein convertase
subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg …
subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg …
Anti‐PCSK 9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
OS Descamps, U Fraass, R Dent… - … journal of clinical …, 2017 - Wiley Online Library
Objectives To put data from our recent systematic review of phase 3 studies of anti‐
proprotein convertase subtilisin/kexin type 9 (PCSK 9) antibodies into the context of clinical …
proprotein convertase subtilisin/kexin type 9 (PCSK 9) antibodies into the context of clinical …
Retargeting the management of hypercholesterolemia–focus on evolocumab
A Colletti, G Derosa, AFG Cicero - Therapeutics and Clinical Risk …, 2016 - Taylor & Francis
Hypercholesterolemia is one of the main risk factors for atherosclerosis and cardiovascular
diseases. The treatment is based on the modification of the diet and lifestyle and if …
diseases. The treatment is based on the modification of the diet and lifestyle and if …